

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Suzanne Crowe
Date of last notice	23 December 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	6 June 2023 (United States) / 7 June 2023 (Australia)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>20,560 CHES Depository Interests in the Company quoted on ASX ("CDIs")</p> <p>12,589 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs")</p> <p>4,350 shares of common stock of the Company (which may be represented by CDIs).</p> <p>2,550 unquoted options in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("Options") expiring 23 Dec 2031 ex USD \$12.18.</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95.</p>
Class	<p>a) RSUs</p> <p>b) Options expiring 7 June 2033, ex USD \$14.17.</p>
Number acquired	<p>a) 6,175 RSUs</p> <p>b) 2,646 Options</p>
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil consideration
No. of securities held after change	<p>20,560 CDIs</p> <p>4,350 shares of common stock of the Company (which may be represented by CDIs).</p> <p>18,764 RSUs</p> <p>2,550 Options expiring 23 Dec 2031 ex USD \$12.18.</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95.</p> <p>2,646 Options expiring 7 June 2033 ex USD \$14.17.</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Options and RSUs as approved by Shareholders at the 2023 Annual Meeting of Stockholders.

Part 2 – Change of director's interests in contracts

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.